|
|
Article: FINANCINGS ROUNDUP PROXIMAGEN DEFIES GLOOMY UK FINANCING TRENDS, RAISES [pounds sterling]50M.
- Article from:
- BIOWORLD Today
- Article date:
- June 8, 2009
- Author:
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Jennifer Boggs, Assistant Managing Editor
Proximagen Neuroscience plc is aiming to raise [pounds sterling]50 million (US$80 million) through the placement of 35.7 million shares, in what the firm said is one of the largest UK biotech financings in the past decade.
On top of that, the London-based company said it is placing the shares at a price of 140 pence each, representing only a small 2 percent discount to its Thursday closing bid price of 142.5 pence.
It's an impressive financing by any account, but particularly in the UK, where firms are struggling to bring in even modest funding rounds, many of which are raised at sizeable ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|